knowledge -WSS

knowledge

author：focus 2025-09-30 09:30:18 - browse：8

Janet Woodcock -- health policy coverage from STAT — Janet Woodcock, the FDA's principal deputy commissioner Chip Somodevilla/Getty Images

WASHINGTON — It’s the end of an era for the Food and Drug Administration’s longtime drug chief, but she’s drawn the battle plans for the agency’s next chapter.

Janet Woodcock joined the FDA’s biologics division in 1986 but soon moved to the drug side, where over nearly three decades, she oversaw hundreds of reviews, new and evolving classes of therapies and several clashes with Congress and patient advocates. In recent years, she also warded off attacks on the agency’s decisionmaking during the Covid-19 pandemic, particularly when the agency veteran took the acting commissioner role during President Biden’s long search for a permanent leader, and took charge of a vast reorganization plan sparked by the baby formula crisis.

Some of those efforts still hang in the balance as she departs this week. Critics argue that under her oversight, the drug division worked too closely with pharmaceutical companies to give broad approvals to new medicines like Biogen’s Aduhelm or so-called accelerated approval to controversial therapies like Sarepta’s Duchenne muscular dystrophy medicine Exondys 51, which is still in the midst of post-marketing studies to prove its effectiveness.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： The pain doctors face in trying to build their families

entertainment

WSS

Patient advocates sound warning on FDA proposal on salt intake

ActiGraph execs on goal of drug approvals with digital endpoints

Listen: Racing for gene therapy & a pioneering approval

A revolution in caring for preterm infants

Wellcome Trust names Røttingen as its new CEO

A fraught question for the kids of Alzheimer’s: Is it coming for us?

entertainment

knowledge

knowledge

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Ukraine taking heavy casualties 10 weeks into its counteroffensive

Apple is now the first public company to be valued at $3 trillion

STAT Readout Newsletter: Today in biotech, life science news

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Readout LOUD podcast: Merger Mondays, Ozempic panic

Moonlake's readout produced a cash windfall. Risks remain

What the Wegovy shortage looks like for doctors — and for patients

Hepatitis C has a cure — but many Americans still lack access to it

Female surgeons have lower rates of long

entertainment

ActiGraph execs on goal of drug approvals with digital endpoints

How clinical AI models' predictive power can degrade over time

Female surgeons have lower rates of long

The pain doctors face in trying to build their families

What's changing in Medicare's open enrollment this year?

Wellcome Trust names Røttingen as its new CEO

entertainment

focus

entertainment

Wikipedia